Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/oo, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$

Name	of entity	
Kazia	Therapeutics Limited ("Kazia")	
ABN 37 06	o ₃ 259 754	
We (t	the entity) give ASX the following	g information.
	1 - All issues ust complete the relevant sections (attack	n sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Employee Share Options
	N 1 C 1	
2	Number of *securities issued or to be issued (if known) or	250,000 options issued today
	maximum number which may be issued	1,200,000 options to be issued upon receipt of shareholder approval

⁺ See chapter 19 for defined terms.

Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

All options have an exercise price of \$0.4047 and expire on 4 January 2024

250,000 options vest as follows:

- 25% on 4 July 2019
- 25% on 4 January 2020
- 25% on 4 July 2020
- 25% on 4 January 2021

1,200,000 options vest as follows:

- 50% (600,000) on issue date
- 16.6% (200,000) on 4 January 2020
- 16.6% (200,000) on 4 January 2021
- 16.6% (200,000) on 4 January 2022
- 4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Apart from the exercise price, vesting dates and expiry date as outlined above, these options rank pari passu with existing employee options.

5 Issue price or consideration

Nil: issued in compensation for services provided

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

The options are issued as part of remuneration for key staff

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

N/A

6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	N/A
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Listing Rule 7.1: 3,102,404 Listing Rule 7.1A: nil Total = 3,102,404
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	250,000 options issued on 4 January 2019 1,200,000 options to be issued upon receipt of shareholder approval

Cross reference: item 33 of Appendix 3B.

⁺ See chapter 19 for defined terms.

8 Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
62,166,673	Ordinary Shares
2 1 40 0 40	Fauity ontions
3,148,948	Equity options

		Number	+Class
		1,856,000	Unlisted convertible notes, with combined face value of \$464,000
		2,906,503	Unlisted options with exercise price of \$4.00 and expiry date of 30 June 2020
9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	46,647	Unlisted options with exercise price of \$1.50 and expiry date of 16/12/2019.
		19,954	Unlisted options with exercise price of \$1.50 and expiry date of 18/12/2019.
		236,667	Unlisted options with exercise price of \$2.20 and expiry date of 16 November 2020
		500,000	Unlisted options with exercise price of \$1.998 and expiry date of 1 February 2021
		250,000	Unlisted options with exercise price of \$2.605 and expiry date of 1 February 2021
		50,000	Unlisted options with exercise price of \$1.63 and expiry date of 5 September 2021
		62,000	Unlisted options with exercise price of \$1.559 and expiry date of 17 October 2021
		16.667	Unlisted options with exercise price of \$1.38 and expiry date of 1 November 2021
		50,000	Unlisted options with exercise price of \$1.376 and expiry date of 23 November 2021
		224,000	Unlisted options with exercise price of \$0.668 and expiry date of 7 August 2022
		440,000	Unlisted options with exercise price of \$0.7802 and expiry date of 5 February 2023
		250,000	Unlisted options with exercise price of \$0.4047 and expiry date of 4 January 2024

⁺ See chapter 19 for defined terms.

10	Dividend policy (in the case of a	
	trust, distribution policy) on the	
	increased capital (interests)	

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee	N/A

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

⁺ See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	N/A
33	⁺ Issue	e date	N/A
		uotation of securitie	S oplying for quotation of securities
34	Type (tick	of *securities one)	
(a)		⁺ Securities described in Part	1
(b)		All other ⁺ securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities	
Entities that have ticked box 34(a) Additional securities forming a new class of securities			
Tick to łocum		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36			y securities, a distribution schedule of the additional umber of holders in the categories
37		A copy of any trust deed for	the additional ⁺ securities

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)		

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 4/1/2019

(Company secretary)

Print name: Kate Hill

== == == ==

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	48,329,621	
 Add the following: Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of 		
securities on different dates as separate line items Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	-	
"A"	48,329,621	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	7,249,443	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of ⁺ equity securities issued or agreed to be issued in that 12-month period <i>not counting</i> those issued:		
Under an exception in rule 7.2		
• Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	4,147,039	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	7,249,443	
Note: number must be same as shown in Step 2		
Subtract "C"	4,147,039	
Note: number must be same as shown in Step 3		
Total ["A" x 0.15] – "C"	3,102,404	

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	48,329,621	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	4,832,962	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of ⁺ equity securities issued or agreed to be issued in that 12-month period under rule 7.1A		
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	4,832,962	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	4,832,962
Note: number must be same as shown in Step 2	
Subtract "E"	4,832,962
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	nil
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.